Source: The Pharma Letter
Taiwan pharma OEP Group has signed an exclusive deal with ADC Therapeutics' joint venture in Shanghai - Overland ADCT - to commercialize Zynlonta (loncastuximab tesirine) in Taiwan and Singapore.
Financial details are not disclosed.
OEP expects the CD19 targeted ADC drug, a treatment for r/r diffuse large B-cell lymphoma, will enrich its cancer drug business which mostly targets solid tumors including breast cancer and oral cancer.
The drug was brought to China in 2020 and is currently in Phase III studies in the country.
The drug was first cleared in the USA in April 2021, for the treatment of adult patients with relapsed or refractory (r/r) large B-cell lymphoma.
Early this year it was licensed to Mitsubishi Tanabe Pharma for the Japanese market, in a deal involving $30 million right away and up to $205 million in milestones.